also on other fortune lists

company facts

f500 stats

Fortune 500

Courtesy of AmerisourceBergen




AmerisourceBergen is the second-largest distributor of pharmaceuticals in the U.S. As such, it’s subject to many of the same forces affecting McKesson, its top competitor. Branded drug price deflation and fewer expected new drug launches continue to put pressure on industry profits, and AmerisourceBergen has been working to counter those effects. The company was founded in 1985 and is headquartered in Chesterbrook, Penn.

Looking for leads, investment insights, or competitive intelligence?


Steven H. Collis

CEO Title

Chairman, President & Chief Executive Officer




Wholesalers: Health Care

HQ Location

Chesterbrook, PA

Years on Fortune 500 List




Figures are for fiscal year ended Sept. 30, 2016.Profile provided by S&P Global.
AmerisourceBergen is also featured in these fortune lists
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$146,8508.0%
Profits ($M)$1,427.9
Assets ($M)$33,656
Total Stockholder Equity ($M)$2,129.4
Market Value — as of March 31, 2017 ($M)$19,229
Profit Ratios
Profit as % of Revenues1.0%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity67.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)6.32
EPS % Change (from 2015)-
EPS % Change (5 year annual rate)20.0%
EPS % Change (10 year annual rate)18.8%
Total Return
Total Return to Investors (2016)-23.3%
Total Return to Investors (5 year, annualized)17.7%
Total Return to Investors (10 year, annualized)15.0%
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about AmerisourceBergen

DEA Whistleblower Blasts Drug Distributors, Congress Over Opioid 'Collusion'

New report highlights revolving door between DEA and industry.

Read More →
As America's Opioid Crisis Spirals, Giant Drug Distributor McKesson Is Feeling the Pain

The company is facing lawsuits from devastated communities in West Virginia.

Read More →
These Pharma Stocks Plunged on Reports of Pending Price Collusion Charges

And the lawmakers who called for the probe now want it expanded to diabetes drugs.

Read More →